RAPP
NASDAQRapport Therapeutics Inc.
Price$36.76+0.55 (+1.53%)
03:00 PM07:45 PM
News · 26 weeks62-73%
2025-12-142026-06-07
Mix2790d
- SEC Filings11(41%)
- Insider9(33%)
- Other5(19%)
- Analyst2(7%)
Latest news
25 items- INSIDERLarge owner Third Rock Ventures V, L.P. sold $743,753 worth of shares (18,572 units at $40.05) as part of a pre-agreed trading plan (SEC Form 4)4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- SECSEC Form 144 filed by Rapport Therapeutics Inc.144 - Rapport Therapeutics, Inc. (0002012593) (Subject)
- PRRapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare ConferenceBOSTON and SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in two upcoming investor conferences. Jefferies Global Healthcare Conference (New York City) – fireside chat on Wednesday, June 3, 2026, at 8:45 am ET. Goldman Sachs 47th Annual Global Healthcare Conference (Miami, FL) – fireside chat on Monday, June 8, 2026, at 1:20 pm ET. Interested parties may access the live and archived webcasts of
- ANALYSTTruist resumed coverage on Rapport Therapeutics with a new price targetTruist resumed coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $56.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Rapport Therapeutics Inc.SCHEDULE 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)
- INSIDERLarge owner Third Rock Ventures V, L.P. sold $5,377,323 worth of shares (133,618 units at $40.24) as part of a pre-agreed trading plan (SEC Form 4)4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- INSIDERLarge owner Third Rock Ventures V, L.P. sold $11,094,906 worth of shares (276,513 units at $40.12) as part of a pre-agreed trading plan (SEC Form 4)4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- SECSEC Form 144 filed by Rapport Therapeutics Inc.144 - Rapport Therapeutics, Inc. (0002012593) (Subject)
- SECSEC Form 144 filed by Rapport Therapeutics Inc.144 - Rapport Therapeutics, Inc. (0002012593) (Subject)
- SECSEC Form 144 filed by Rapport Therapeutics Inc.144 - Rapport Therapeutics, Inc. (0002012593) (Subject)
- SECSEC Form 10-Q filed by Rapport Therapeutics Inc.10-Q - Rapport Therapeutics, Inc. (0002012593) (Filer)
- SECRapport Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)
- PRRapport Therapeutics Reports First Quarter 2026 Financials and Provides Business UpdatePhase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seizure reduction, including a 90% median reduction in clinical seizures over baseline in weeks 9-12 RAP-219 Phase 2 trial in bipolar mania topline results now expected in the fourth quarter of 2026, ahead of previous 1H 2027 guidance RAP-219 Phase 3 program in FOS remains on track for initiation in the second quarter of 2026 Pipeline programs, including RAP-219 long-acting injectable formulation, RAP-219 in primary generalized tonic-clonic seizures, and α6β4 nAChR in chronic pain and migraine, continue to advance Strategic collaboration and license agreement entered into with Tenacia Biotech
- SECSEC Form DEFA14A filed by Rapport Therapeutics Inc.DEFA14A - Rapport Therapeutics, Inc. (0002012593) (Filer)
- SECSEC Form DEF 14A filed by Rapport Therapeutics Inc.DEF 14A - Rapport Therapeutics, Inc. (0002012593) (Filer)
- INSIDERSEC Form 4 filed by Third Rock Ventures V, L.P.4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- INSIDERSEC Form 4 filed by Yeleswaram Krishnaswamy4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- SECRapport Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)
- PRRapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual MeetingClinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical seizures over baseline in weeks 9-12 and a 59% median reduction in clinical seizures over baseline in weeks 13-16 New data demonstrate that RAP-219 has a half-life of approximately 22 days RAP-219 was generally well tolerated throughout treatment and follow-up periods BOSTON and SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric dis
- SECSEC Form 144 filed by Rapport Therapeutics Inc.144 - Rapport Therapeutics, Inc. (0002012593) (Subject)
- INSIDERSEC Form 4 filed by Yeleswaram Krishnaswamy4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- ANALYSTRaymond James initiated coverage on Rapport Therapeutics with a new price targetRaymond James initiated coverage of Rapport Therapeutics with a rating of Strong Buy and set a new price target of $66.00
- INSIDERSEC Form 4 filed by Yeleswaram Krishnaswamy4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- PRRapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual MeetingBOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will present results from its Phase 2a trial of RAP-219 in patients with focal onset seizures (FOS), including new data from the 8-week follow-up period, in a podium presentation at the upcoming 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22 in Chicago. Presentation Details Title: Efficacy and Tolerability of RAP-219, a Potential
- INSIDERSEC Form 4 filed by Gault Cheryl4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
RAPP FAQ
6 questionsWhere does RAPP stock trade?
Rapport Therapeutics Inc. (RAPP) is listed on NASDAQ.What sector and industry is RAPP in?
Rapport Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Rapport Therapeutics Inc. go public?
Rapport Therapeutics Inc. (RAPP) completed its IPO in 2024.What are analysts saying about RAPP?
Rapport Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Truist: Buy on 2026-05-19. Recent price targets range from $3100.00 to $4700.00.What companies are similar to RAPP?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare RAPP side-by-side with any of them on Quantisnow.How can I track RAPP on Quantisnow?
Quantisnow aggregates Rapport Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RAPP to receive live email and push alerts on every new disclosure.